BHAT vs GIBO

The Advanced Deterministic Scorecard reveals a critically weak financial health profile with a Piotroski F-Score of just 3/9, indicating poor operational and balance sheet strength. Despite a remarkably high current ratio of 23.03 and low debt/equity of 0.04, the company is deeply unprofitable, with a profit margin of -47.88% and ROE of -14.99%, severely undermining its valuation. Revenue growth is negligible at 1.90% YoY, while the stock has lost nearly all value over the past five years (-99.9%), and trading metrics are largely unavailable due to financial opacity. Compared to sector peers, BHAT lags in growth, profitability, and market confidence, with no analyst coverage or target prices, reinforcing a high-risk profile.

GIBO exhibits extreme financial distress, highlighted by a weak Piotroski F-Score of 2/9 and a critical lack of liquidity. The company reports 0.00% across all margin metrics and a Quick Ratio of 0.06, indicating a severe inability to meet short-term obligations. Long-term price performance is catastrophic, with a -99.9% decline over the last year, three years, and five years. With no analyst coverage and a Price/Book ratio of 10.84 despite zero profitability, the stock appears fundamentally decoupled from value.